Guggenheim Reiterates "Buy" Rating for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at Guggenheim in a report issued on Wednesday,Benzinga reports.

A number of other equities analysts have also recently weighed in on the company. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target for the company. Finally, Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Pfizer Price Performance

PFE stock traded down $0.32 during midday trading on Wednesday, reaching $25.67. The company had a trading volume of 4,616,693 shares, compared to its average volume of 39,374,109. The firm has a 50-day moving average price of $26.29 and a 200-day moving average price of $27.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $145.47 billion, a P/E ratio of 18.21, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The firm's revenue was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the stock. Swedbank AB grew its holdings in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock worth $166,284,000 after acquiring an additional 37,636 shares during the period. United Bank grew its stake in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 1,277 shares during the period. WCM Investment Management LLC raised its holdings in Pfizer by 337.2% in the third quarter. WCM Investment Management LLC now owns 50,675 shares of the biopharmaceutical company's stock worth $1,474,000 after purchasing an additional 39,085 shares in the last quarter. Entropy Technologies LP purchased a new position in Pfizer during the third quarter valued at $860,000. Finally, GSA Capital Partners LLP lifted its position in Pfizer by 87.6% during the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company's stock valued at $949,000 after buying an additional 15,310 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.